In an April 18, 2015 press release, Achelios Therapeutics (http://achelios.com/) announced that it will present, on April 22, 2015, results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN™, the company's proprietary topical anti-migraine therapy. The data to be presented demonstrate that the simple application of a well-known non-steroidal anti-inflammatory drug (NSAID), using the company's proprietary formulation, on the skin, over the trigeminal nerve branches, can be a safe and effective alternative treatment for patients suffering from acute migraine. William R. Bauer, M.D., Ph.D., FAAN, a neurologist and migraine headache specialist and advisor to Achelios, said, "Migraine remains a significant global cause of disability and disruption of activities of daily living. TOPOFEN results show promise to provide a safe and effective treatment that will positively impact the disabling effects of such a condition." The results of the clinical trial will be presented at the Emerging Science session of the American Academy of Neurology annual meeting in Washington, D.C., on Wednesday, April 22, 2015. The study was conducted by scientists from Achelios and the Michigan Headache & Neurological Institute in Ann Arbor, Michigan. Wolfgang Liedtke, M.D., Ph.D., from Duke University will present the results as a member of the team that conducted the research and a paid advisor to Achelios. Dr. Liedtke, an Associate Professor of Neurology and Attending Physician in the Duke Pain Medicine clinics, said, "The results of the study are encouraging, and those of us who treat migraine think it may lead to a meaningful alternative treatment for a substantial number of migraineurs.Login Or Register To Read Full Story